This technology utilizes 4-methoxycinnamic acid as an active ingredient in pharmaceutical compositions for preventing and treating obesity and hypertension in subjects with reduced p-AMPK or UCP-1 expression, as well as compositions for fatigue recovery and vitality. This ingredient is also used in research reagent compositions that increase p-AMPK and PGC-1α expression.
With the abundance of modern diets, the prevalence of metabolic syndrome—where two or more conditions like obesity, type 2 diabetes, hypertension, and hyperlipidemia overlap—has reached approximately 30% in both men and women, making heart disease and stroke leading causes of death. Chronic fatigue is also a root cause of various illnesses, yet there is a lack of safe, low-side-effect therapeutic and supplementary materials that address both metabolic diseases and fatigue.
This technology leverages the principle that 4-methoxycinnamic acid phosphorylates AMPK, a key regulator of energy metabolism, and increases the secretion of PGC-1α and the thermogenic protein UCP-1, thereby reducing lipid accumulation, fatty acid synthase (FAS) production, and TNFα-induced inflammation. Simultaneously, it increases intracellular ATP production to reduce fatigue and can be formulated at 1 to 50 parts by weight per 100 parts of the composition. Applicable to obesity and hypertension treatments, fatigue-recovery health supplements, and AMPK-activating research reagents, it offers the dual benefits of body fat reduction and energy production from a single, naturally derived ingredient.
N/A
